Molecular analysis of FMR1 reactivation in fragile-X induced pluripotent stem cells and their neuronal derivatives

Journal of Molecular Cell Biology

Volumn 4, Issue 3, 2012, Pages 180-183

  Bar Nur, Ori ^a   Caspi, Inbal ^a   Benvenisty, Nissim ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; FRAGILE X MENTAL RETARDATION PROTEIN; TRICHOSTATIN A;

CELL CULTURE; CELL DIFFERENTIATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; DRUG EFFECT; EPIGENETICS; FRAGILE X SYNDROME; HUMAN; LETTER; PLURIPOTENT STEM CELL; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CELL DIFFERENTIATION; CELLS, CULTURED; CHROMATIN ASSEMBLY AND DISASSEMBLY; EPIGENESIS, GENETIC; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDUCED PLURIPOTENT STEM CELLS; MICE; NEURONS;

EID: 84861849462     PISSN: 16742788     EISSN: 17594685     Source Type: Journal    
DOI: 10.1093/jmcb/mjs007     Document Type: Letter

References (12)

1. Brouwer, J.R., Mientjes, E.J., Bakker, C.E., et al. (2007). Elevated Fmr1 mRNA levels and reduced protein expression in a mouse model with an unmethylated fragile X full mutation. Exp. Cell Res. 313, 244-253.
2. Coffee, B., Zhang, F., Warren, S.T., et al. (1999). Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells. Nat. Genet. 22, 98-101.
3. Crawford, D.C., Acunã, J.M., and Sherman, S.L. (2001). FMR1 and the fragile X syndrome: human genome epidemiology review. Genet. Med. 3, 359-371.
4. De Rubeis, S., and Bagni, C. (2011). Regulation of molecular pathways in the fragile X syndrome: insights into autism spectrum disorders. J. Neurodev. Disord. 3, 257-269.
5. Eiges, R., Urbach, A., Malcov, M., et al. (2007). Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos. Cell Stem Cell 1, 568-577.
6. Marchetto, M.C., Carromeu, C., Acab, A., et al. (2010). A model for neuronal development and treatment of Rett syndrome using human induced pluripotent stem cell. Cell 143, 529-537.
7. Rudek, M.A., Zhao, M., He, P., et al. (2005). Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J. Clin. Oncol. 23 3906-3911.
8. Schuldiner, M., Eiges, R., Eden, A., et al. (2001). Induced neuronal differentiation of human embryonic stem cells. Brain Res. 913, 201-205.
9. Sutcliffe, J.S., Nelson, D.L., Zhang, F., et al. (1992). DNA methylation represses FMR-1 transcription in fragile-X syndrome. Hum. Mol. Genet. 1, 397-400.
10. Urbach, A., Bar-Nur, O., Daley, G.Q., et al. (2010). Differential modeling of fragile X syndrome by human embryonic stem cells and induced-pluripotent stem cells. Cell Stem Cell 6, 407-411.
11. Verkerk, A.J., Pieretti, M., Sutcliffe, J.S., et al. (1991). Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65, 905-914.
12. Yamanaka, S. (2008). A fresh look at iPS cells. Cell 137, 13-17.